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Abstract
The natural peptide N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) decreases inflammation in chronic diseases such as hypertension and heart failure. However, Ac-SDKP effects
on acute inflammatory responses during myocardial infarction (MI) are unknown. During the
first 72 hours post-MI, neutrophils, M1 macrophages (pro-inflammatory), and M2 macrophages (pro-resolution) and release of myeloperoxidase (MPO) and matrix metalloproteinases (MMP) are involved in cardiac rupture. We hypothesized that in the acute stage of MI,
Ac-SDKP decreases the incidence of cardiac rupture and mortality by preventing immune
cell infiltration as well as by decreasing MPO and MMP expression. MI was induced by ligating the left descending coronary artery in C57BL/6 mice. Vehicle or Ac-SDKP (1.6 mg/kg/d)
was infused via osmotic minipump. Cardiac immune cell infiltration was assessed by flow
cytometry, cardiac MPO and MMP levels were measured at 24–48 hrs post-MI. Cardiac rupture and mortality incidence were determined at 7 days post-MI. In infarcted mice, Ac-SDKP
significantly decreased cardiac rupture incidence from 51.0% (26 of 51 animals) to 27.3%
(12 of 44) and mortality from 56.9% (29 of 51) to 31.8% (14 of 44). Ac-SDKP reduced M1
macrophages in cardiac tissue after MI, without affecting M2 macrophages and neutrophils.
Ac-SDKP decreased MMP-9 activation in infarcted hearts with no changes on MPO expression. Ac-SDKP prevents cardiac rupture and decreases mortality post-acute MI. These protective effects of Ac-SDKP are associated with decreased pro-inflammatory M1
macrophage infiltration and MMP-9 activation.

Introduction
More than 1.5 million people suffer acute myocardial infarction (MI) annually in the United
States. About 30% of those patients die within the first 24 hours due to arrhythmias or pump
failure. Cardiac rupture is an uncommon but fatal complication in humans. In rodents cardiac
rupture is much more common, being between 30 and 60% during the first week post-MI [1].
The structural changes in the extracellular matrix (ECM) during acute inflammation are
thought to cause cardiac rupture after myocardial infarction. Matrix metalloproteinases
(MMP), a family of zinc-containing endoproteinases released mainly by leukocytes, play a key
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role in degrading the ECM of the heart [2]. Specifically, MMP-9, a 92kDa gelatinase, is involved
in not only in ECM breakdown, but also leukocyte cardiac invasion, cytokine activation, and
angiogenesis. MMP-9 and innate immune cells are both required for the development of cardiac rupture in MI [3, 4]. Acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) is a naturally occurring
acetylated tetrapeptide that exert cardioprotective effects in several cardiovascular and renal diseases when it is exogenously administered [5, 6]. The 43 aminoacid peptide thymosin β4 (Tβ4)
carries Ac-SDKP sequence on its N-terminal end and its enzymatic cleavage is the main source
of Ac-SDKP. It has been reported that in MI, Tβ4 treatment diseases mortality and cardiac dysfunction concomitant with reduced neutrophil and macrophage infiltration [7]. It is not known
whether Ac-SDKP mediates some of the cardioprotective effects of Tβ4. Previous studies
showed that the chronic infusion of Ac-SDKP reduces cardiac remodeling in infarcted rats [8].
However, in this study the effects of Ac-SDKP on the prevalence of cardiac rupture and mortality were not evaluated since rats do not develop cardiac rupture. We hypothesized that in the
acute stage of MI, Ac-SDKP decreases the incidence of cardiac rupture and mortality by modulating the innate immune response and by preventing the ECM degradation. Furthermore, we
evaluated whether Ac-SDKP modulates the differentiation of macrophages towards the proinflammatory M1 or reparative/pro-fibrotic M2 phenotypes.

Material and methods
Animals
Twelve-week-old male C57BL/6 mice (25–30 g, The Jackson Laboratory, Bar Harbor, ME)
were housed in vented cages with a 12:12-h light-dark cycle and given standard chow (0.4%
sodium) and tap water. They were allowed 7 days to adjust to their new environment. All protocols were approved by the Institutional Animal Care and Use Committee of Henry Ford
Health System.

Experimental protocols
Mice were anesthetized with pentobarbital sodium (50 mg/kg ip), and an Alzet osmotic minipump (Durect, Cupertino, CA) containing either saline or Ac-SDKP (1.6 mgkg−1day−1) was
implanted intraperitoneally at least 48 hours before MI induction. The dose and drug delivery
route were based on previous studies of Ac-SDKP [6, 9]. MI was surgically induced by ligating
the left anterior descending coronary artery as previously described [7, 10]. To evaluate cardiac
rupture incidence and infarct size, treatments were continued for 7 days. The presence of a
large amount of blood in the chest cavity and perforation of the infarct-free wall were criteria
of death due to cardiac rupture. To evaluate the Ac-SDKP effects on acute inflammation, the
animals were studied for 2 days after MI was induced.

Infarct size
The effect of Ac-SDKP on infarct size was determined at 7 days post-MI as described previously [11]. Briefly, a 6-μm section from each cardiac tissue slice was stained with Gomori Trichrome to identify fibrous tissue (infarction). Infarct size was calculated as a percentage of the
infarcted area divided by the entire LV area.

Immunohistochemistry of cell infiltration
At 24–48 hours post-MI, mice were anesthetized with pentobarbital sodium (50 mg/kg, ip)
then the whole heart was perfused with ice-cold PBS for 3 minutes. The heart was sectioned transversely into 3 slices, and the middle section was fixed in formalin. The sections were epitope-
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retrieved and immunostained with anti-Ly-6g/c antibody, clone: NIMP-R14 (Abcam, Cambridge,
MA). Negative controls were processed in a similar fashion, but were not incubated with the primary antibody. All measurements and analyses were performed in a blinded fashion.

Flow cytometry analysis of immune cells in bone marrow, peripheral blood,
and myocardium
Mice were sacrificed at 48 hours post MI. Animals were anesthetized with pentobarbital
sodium (50 mg/kg ip). Bone marrow cells from tibias and femurs were collected by flushing
the bones with 1 ml PBS. Blood was collected from vena cava, and red blood cells were lysed
with ACK lysis buffer. PBS-perfused hearts were enzymatically digested with 0.05% collagenase II (Worthington Biochemical Corporation, Lakewood, NJ), 0.005% elastase (Worthington Biochemical Corporation, Lakewood, NJ), and 10 μg/ml DNase (Sigma Aldrich, St. Louis,
MO) for 30 minutes at 37˚ C. Cells were passed through 70-μm nylon mesh and separated by
percoll centrifugation. Cells were blocked with anti-CD16/32 antibody for 5 minutes, then
immunostained with anti-mouse CD45 PercP-Cy5.5, anti-mouse CD11b Alexa fluor 700, antimouse F4/80 Alexa fluor 488, anti-mouse Ly-6g APC-Cy7, and anti-mouse CD206 PE antibodies. All antibodies were purchased from Biolegend (San Diego, CA). To exclude dead cells,
LIVE/DEAD1 Fixable Aqua Dead Cell Stain Kit was used (Invitrogen, Carlsbad, CA). Count
Bright Absolute Counting Beads (Invitrogen, Carlsbad, CA) were used to calculate the results
as the absolute infiltrating cell number per whole tissue (heart). Data were acquired using a BD
Fortessa flow cytometer then neutrophils, total macrophages, and M1/M2 macrophage phenotypes were analyzed as described by Yan X et al.[12].

In vitro neutrophil chemotaxis assessment
Cell chemotaxis was evaluated by transwell migration assay using the differentiated HL-60
myeloid cell line purchased from American Type Culture Collection (ATCC, Manassas, VA).
Cells were grown in Iscove’s modified Dulbecco’s medium (IMDM) containing 10% fetal
bovine serum. HL-60 cells were differentiated into neutrophil-like cells by adding 1.3% DMSO
in IMDM. Cells were incubated with vehicle, Ac-SDKP (100 nM), or Tβ4 (20 nM) as a positive
control for 15 minutes before the chemotaxis assay. 0.5 million cells were placed in the upper
transwell chamber, and a chemoattractant peptide, fMLP (1 nM), was added into the bottom
chamber. After 3 hours of incubation, migrated cells were quantified in the bottom chamber
using a Neubauer hemocytometer.

Cardiac myeloperoxidase activity
Frozen heart samples (20–50 mg) were homogenized in 0.5 ml phosphate buffered saline using
a dounce homogenizer. Samples were sonicated and centrifuged at 10,000 x g for 10 min at
4˚C. Protein concentration in the supernatants was determined by the Bradford method. Samples (0.5 mg of total protein) were concentrated with Amicon Ultra 30K centrifugal filters. We
used the myeloperoxidase chlorination fluorometric assay kit (Cayman Chemical) to determine MPO activity following the manufacturer’s protocol. MPO was expressed as relative fluorescence units (RFU) per minute per mg protein.

Zymogram
Freshly isolated heart tissues were homogenized in ice-cold extraction buffer containing 10
mM cacolydic acid, 0.15 M NaCl, 20 mM ZnCl2, 1.5 mM NaN3, 1% Triton X-100 (pH 5.0)
with a proteinase inhibitor cocktail set III (EMD Millipore). Samples were centrifuged at
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14,000 x g for 10 min at 4˚ C, and protein concentration was determined by Bradford method
in the supernatants. Twenty micrograms of protein were loaded in 10% zymographic gel (Invitrogen). Gels were incubated with renaturing buffer (2.5% triton X-100) at room temperature
for 30 minutes. Gels were incubated in developing buffer (50 mM Tris-HCl pH 8.0, 5 mM
CaCl2, 0.2 NaCl, 0.02% Brij-35) for 16 hours at 37˚ C. Gels were stained in 0.05% coomasie
blue solution, then washed with destaining buffer (5% acetic acid, 10% methanol) until sharp
bands were visible. Gels were scanned, and bands density was analyzed with Image J software.

ELISA
Freshly isolated heart tissues were homogenized in ice-cold extraction buffer containing 20
mM HEPES pH 7.5, 2 mM EDTA, 1.5 M NaCl, complete mini EDTA-free proteinase inhibitor
and phosSTOP phosphatase inhibitor (Roche) using a dounce homogenizer. Samples were
sonicated and centrifuged at 10,000 x g for 10 min at 4˚C. Protein concentration in the supernatants was determined by the Bradford method. IL-1β and the specific endogenous tissue
inhibitor of metalloproteinases, TIMP-1, were measured in samples (0.5 mg of total protein)
using ELISA kits from R&D systems.

Statistical analysis
Binary data (cardiac rupture and mortality) were expressed as proportions, and groups were
compared using a chi-squared test. For cardiac rupture and mortality we proposed to sample a
total of 100 animals. This would have resulted in the paired t-test having 80% power, with a
two-sided 0.05 alpha level to detect a small effect size of 0.28. In this setting, the effect size represents the detectable difference in standard deviation units. If we assume a high satisfaction
rate of 80% then the sample size results in a confidence interval half-width of 8%.
Continuous data are expressed as means ± SE. The data violated the assumptions of the
parametric test so we utilized a nonparametric test in its place. An adjustment on the significance criteria is made, using Hochberg’s approach, which is a reasonable approach. An overall
test, such as Kruskal-Wallis test, was not utilized since these overall tests are not informative as
we are interested in pairwise contrasts and not a global hypothesis. It is a reasonable approach
to just examine the pairwise contrasts as long as an adjustment is made on the rejection criteria. Adjusted P values of < 0.05 were considered significant. The sample size was determined
based on our previous experience. Groups of n = 10 are appropriate for the physiological
experiments to ensure a minimum of 8 mice per group complete the protocols. Based on our
previous experience, n = 8 provided sufficient power (80% or higher) to detect small changes
in the parameters measured in this study with a P-value of 0.05 or less.
All statistical analysis were performed by the Biostatistics core at the Department of Public
Health Sciences, Henry Ford Hospital, Detroit, Michigan.

Results
Effect of Ac-SDKP on cardiac rupture and mortality after MI
MI was performed in 109 mice, 14 animals (12.8%) were excluded from analysis: 6 animals
because died during surgery and 8 animals because of not having MI on autopsy. Out of 95
mice analyzed at 7 days post-MI, 38 of those died from cardiac rupture and 5 died from other
causes. In vehicle treatment group, the mortality rate was 56.9% and the prevalence of cardiac
rupture was 51.0% (26 out of 51 animals). In Ac-SDKP treated animals the prevalence of cardiac rupture (27.3%, 12 out of 44 animals, p = 0.015, Fig 1) and the mortality rate (31.8%,
p = 0.019, Fig 1B) was significantly lower in comparison to vehicle treated animals. In a
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Fig 1. Effect of Ac-SDKP on cardiac rupture incidence, mortality rate, and infarct size in myocardial infarction.
Out of 95 mice analyzed at 7 days post-MI, 38 died from cardiac rupture, and 5 died from other causes. In myocardial
infarction, Ac-SDKP decreased A) incidence of cardiac rupture from 51.0% (vehicle treated) to 27.3% (Ac-SDKP
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treated) and B) mortality from 56.9% (vehicle treated) to 31.8% (Ac-SDKP treated). C) In a new group of 25 animals,
Ac-SDKP tends to decrease infarct size, but it does not reach statistical significance (p = 0.13; power < 0.70).
https://doi.org/10.1371/journal.pone.0190300.g001

different cohort of 25 animals we tested the effects of Ac-SDKP on infarct size. Although there
was not difference between the vehicle vs Ac-SDKP treated animals, there is a trend that AcSDKP tends to decrease the infarct size (p = 0.13, power of test < 0.07; Fig 1C).

Effect of Ac-SDKP in myocardial inflammatory cell infiltration after acute
MI
Immunohistochemical analysis of cardiac tissues after 24–48 hours post MI using anti-Ly-6g/c
antibody, a myeloid cell derived marker, revealed a prominent myocardial infiltration by
immune cells. Infusion of Ac-SDKP from 3 days before the surgery prevented the infiltration
by immune cells in MI (Fig 2A and 2B). Since Anti-Ly-6g/c antibody recognizes both neutrophils and monocytes in a separate cohort of mice we performed flow cytometry analysis to
identify the phenotype of these cells (Fig 3A). Using cell specific antibodies we observed that in
MI both neutrophils and monocytes were increased. Pre-treatment with Ac-SDKP did not
affect neutrophil infiltration (Fig 3B) but it reduced the number of macrophages (Fig 3C).
During the acute stage of MI (24–48 hours) the M1 pro-inflammatory phenotype was dominant over M2 anti-inflammatory macrophages. Ac-SDKP decreased M1 macrophages but it
did not affect M2 macrophages. No changes in the M1/M2 ratio was observed (Fig 3D). The
treatment with Ac-SDKP had no effect in sham operated animals.

Effect of Ac-SDKP in myeloid derived cells in bone marrow and peripheral
blood after acute MI
The flow cytometry analysis showed not differences in neutrophil population in bone marrow
after the MI (Fig 4A and 4B). However, in peripheral blood we observed that myocardial
infarction (MI) induced an increase in neutrophils, that was not restored by neither Ac-SDKP
or Tβ4 infusion (Fig 4D). Peripheral blood monocytes (Ly6g-) tend to increase after the MI,
and both Ac-SDKP and Tβ4 tended to restore the amount monocytes after MI, however these
differences were not statistically significant (Fig 4E).

Effect of Ac-SDKP and Tβ4 on neutrophil chemotaxis
The effect of Ac-SDKP and Tβ4 on neutrophil chemotaxis was assessed in vitro by transwell
chemotaxis assay. As shown in Fig 5A we observed that Tβ4, but not Ac-SDKP, inhibited neutrophil migration induced by the formylated peptide fMLP.

Effect of Ac-SDKP on myeloperoxidase (MPO) and MMP-9 in MI
We tested the effect of Ac-SDKP and Tβ4 at a dose of 1.6 mg/kg/day on myocardial MPO
activity at 24 hours post MI. As shown in Fig 5B, MPO activity was increased in MI in comparison to sham operated animals. Tβ4, but not Ac-SDKP, prevented the increase in MPO activity
in infarcted hearts.

Zymography
An increase in MMP-9 levels were observed in infarcted mice at 48 hours post-MI, and AcSDKP diminished this increase. No significant alterations in MMP-2 activity was observed in
either sham or MI groups (Fig 6A and 6B).

PLOS ONE | https://doi.org/10.1371/journal.pone.0190300 January 24, 2018

6 / 16

Ac-SDKP prevents cardiac rupture

Fig 2. Effects of Ac-SDKP on cardiac inflammatory cell infiltration in myocardial infarction. A) Representative photoraphs of
myocardial sections stained for Ly-6C/G (neutrophil/monocyte marker) from sham and 24 h post-myocardial infarction (MI). AcSDKP infusion started 48 h before surgery. Magnification was 20x. Only Ly-6g/c positive (brown) cells with visible nuclei were
counted. Photographs of the whole section surface were taken. Analysis was performed blinded. B) Quantitative data of myocardial
Ly-6C/G positive cells expressed as cells per mm2. In MI, Ac-SDKP blunted neutrophil/monocyte infiltration.
https://doi.org/10.1371/journal.pone.0190300.g002
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Fig 3. Effects of Ac-SDKP on cardiac neutrophils and macrophages in myocardial infarction. Cardiac infiltration by neutrophils and macrophages was
analyzed by flow cytometry at 2 days post-myocardial infarction (MI). A) Gating strategy: After gating for live cells using viability dye, total myeloid cells
(CD45+ CD11b+) were gated. Macrophages were identified as F4/80+ Ly-6g- cells whereas neutrophils were identified as F4/80- Ly-6g+ cells. Using Count
Bright Absolute Counting Beads (Invitrogen, Carlsbad, CA) total neutrophils (B) and macrophages (C) per heart were quantified. Ac-SDKP significantly
reduced expansion of cardiac macrophage but not neutrophil populations in MI. The pro-inflammatory M1 and pro-fibrotic/reparative M2 polarization (D)
was analyzed in the total macrophage (F4/80+) gate. Both, M1 (CD206-) and M2 (CD206+) were increased in MI. Ac-SDKP prevented the increase in M1
macrophages and tended to decrease M2 macrophages.
https://doi.org/10.1371/journal.pone.0190300.g003
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Fig 4. Evaluation of innate immune cells in bone marrow and peripheral blood by flow cytometry analysis. A) Representative
flow cytometry analysis of bone marrow. Neutrophils were identified as CD11b+Ly6g+. B). Ac-SDPK and thymosin β (Tβ4) do not
affect bone marrow neutrophil mobilization in myocardial infarction (MI). C) Representative flow cytometry analysis of peripheral
blood. Neutrophils were identified as CD11b+ Ly6g+ and monocytes were CD11b+ Ly6g-. MI induced increased peripheral blood
neutrophils (D), but did not affect circulating monocytes (E). Tβ4 tends to decrease both neutrophils and monocytes, whereas AcSDKP tends to decrease monocytes (these differences were not statistically significant).
https://doi.org/10.1371/journal.pone.0190300.g004
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Fig 5. Effects of Ac-SDKP and thymosin β (Tβ4) on neutrophils in vitro and in vivo. A) Transwell assays were
conducted to evaluate the effect of Ac-SDKP and Tβ4 on fMLP-induced neutrophil (HL-60 cell line) chemotaxis in
vitro. Tβ4, but not Ac-SDKP, inhibited fMLP-induced neutrophil chemotaxis. B) cardiac myeloperoxidase (MPO)
activity was measured at 48 hours post-myocardial infarction (MI). Tβ4, but not Ac-SDKP, prevented MPO activation
in MI.
https://doi.org/10.1371/journal.pone.0190300.g005

Effect of Ac-SDKP on cardiac TIMP-1 and IL-1β
The specific endogenous tissue inhibitor metalloproteinase TIMP-1 and IL-1β were measured
by ELISA at 48 hours post-MI. Both, TIMP-1 and IL-1β were significantly increased in MI.
Ac-SDKP reduced TIMP-1 but has not effect on IL-1β in infarcted animals (Fig 7A and 7B).

Discussion
The present study aims to describe the effects of Ac-SDKP during the acute stage of MI. ACE
inhibitors are one of the most effective drugs to alleviate cardiac inflammation and remodeling
in MI. Ac-SDKP is a compelling peptide to treat cardiovascular diseases since its endogenous
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Fig 6. Effects of Ac-SDKP on cardiac matrix metalloproteinase (MMP) activity in myocardial infartion. Ac-SDKP
effects on MMP activity were measure by zymography A) Representative figure of zymograms. White bands represent
degradation of gelatin matrix, indicating enzymatic activity. Myocardial infarction activated MMP-9 (~ 92 kDa
protein) but the band corresponding to MMP-2 activity (~ 62 kDa protein) was not observed (confirmed using a
positive control, data not shown). Ac-SDKP significantly decreased MMP-9 activity in infarcted animals. B)
Quantitative data were obtained by measuring band optical intensity.
https://doi.org/10.1371/journal.pone.0190300.g006

plasma levels increase with ACE inhibitors. Although ACE inhibitors mainly target the reninangiotensin system, there is evidence indicating that Ac-SDKP is required for ACE inhibitors
cardioprotective effects. We and others previously reported that Ac-SDKP inhibits interstitial
collagen deposition [13, 14]. Because collagen deposition is required for maintaining structural
integrity of the infarcted ventricle [15] we predicted that Ac-SDKP could exacerbate cardiac
rupture in mice. On the other hand, anti-inflammatory properties of Ac-SDKP predicts significant benefits in MI. Mice treated with Ac-SKDP and subjected to MI showed a reduced cardiac rupture and mortality compared with vehicle treated mice. Cardiac repair after MI results
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Fig 7. Effects of Ac-SDKP on cardiac interleukin 1β (IL-1β) and endogenous tissue inhibitors of metalloproteinases
(TIMP-1). A) IL-1β was measured by ELISA at 48 hours post-myocardial infarction (MI). There was a significant increase
in IL-1β expression in MI. Ac-SDKP did not prevent increased in IL-1β. B) Measurement of TIMP-1 at 48 hours post-MI
by ELISA indicated that the increase in TIMP-1 in MI is reduced by Ac-SDKP.
https://doi.org/10.1371/journal.pone.0190300.g007

from several events initiated by neutrophils and macrophages (inflammatory phase) that serves
to clear damaged cells and extracellular matrix tissue (3–4 d in mice), followed by a reparative
phase with resolution of inflammation, scar formation, and neovascularization over the next
several days [15, 16]. Depletion of neutrophils either with hydroxycarbamide or genetic
removal of MPO completely prevents cardiac rupture [3, 4]. Tβ4 is an endogenous 43 amino
acid peptide containing Ac-SDKP sequence in its N-terminal end. The enzymatic hydrolysis
of Tβ4 by meprin and prolyl oligopeptidase releases Ac-SDKP. Previously, Peng et al. demonstrated that Tβ4 prevents cardiac rupture in MI [7] and in the present study we observed that
Tβ4 suppresses neutrophil mobilization in vivo and in vitro. We initially hypothesized that AcSDKP may mediate the effects of Tβ4 on neutrophils, but conversely we observed that AcSDKP did not decrease neutrophil chemotaxis nor MPO activity, indicating that Ac-SDKP
might not be involved in Tβ4 effects at least on neutrophil function. This is important because
Tβ4 cleavage releases different peptides besides Ac-SDKP, such as AGES [17], and dissecting
the effects of each Tβ4 fragment will be crucial for designing new therapeutic compounds with
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specific actions. During the acute ischemic event, macrophage expansion occurs, likely
through both local macrophage proliferation and circulating monocyte recruitment [18]. Infiltrated macrophages exhibit biphasic activation after MI; pro-inflammatory M1 macrophages
peak at MI 3 days, whereas M2 macrophage (pro-fibrotic/reparative) peak at MI 7 days [19].
We found a massive expansion of M1 macrophages at 48 hours post-MI and this increase was
suppressed by Ac-SKDP. These observations are not surprising since Sharma et al showed that
Ac-SDKP inhibits macrophage differentiation, mobilization, and TNF-α release in vitro [20].
M2 macrophages play an important role in the tissue repair after cardiac ischemic injury [21].
Ac-SDKP analog, Ac-SDDKDP, improves cardiac function but paradoxically attenuates M2
macrophages [22]. Similarly, we observed that Ac-SDKP tended to decrease M2 pro-reparative
macrophages. We speculate that the Ac-SDKP decrease in M2 response could be led by the
attenuation of inflammatory environment, that is necessary for the M2 polarization. MMP are
capable of degrading cardiac extracellular matrix [2]. Mice deficient in MMP-9 are protected
from cardiac rupture (Heymans et al., 1999), indicating that MMP-9 plays a role in early myocardial healing. We observed that MMP-9 was activated during the acute phase of MI, and
this increase was blunted when the mice were treated with Ac-SDKP. Thus, Ac-SDKP might
decrease the incidence of cardiac rupture by preventing the degradation of the extracellular
matrix. MMP-9 is released by neutrophils and macrophages, and reduced MMP-9 levels could
result from decreased immune cell infiltration. However, MMP-9 also contributes to immune
cell infiltration, indicating that there is a positive loop between them. One can argue that AcSDKP might be detrimental at the chronic stage of MI because MMP-9 deletion prevents cardiac rupture in the short term, but also inhibits angiogenesis in the reparative phase [3]. Interestingly, long term effects of Ac-SDKP include pro-angiogenic effects [23] and improvement
of cardiac function [5, 8]. Ac-SDKP exerts multiple effects in various inflammatory as well as
cell repair mechanisms, and the activation/inactivation of all these factors do not occur simultaneously. Thus, MMP inactivation might not necessarily the only mechanism mediating
Ac-SDKP effects in MI. TIMP are endogenous inhibitors of MMP-9 and participates in their
regulation. Similarly, pro-inflammatory cytokines are positive regulators of MMP-9. Thus,
Increased TIMP or decreased pro-inflammatory cytokines could explain how Ac-SDKP interferes with MMP-9 activation. Interestingly, Ac-SDKP did not increased TIMP-1 neither
decreased IL-1β. In cardiac fibroblasts Ac-SDKP inhibits IL-1β-induced MMP-9 activity
(Rhaleb et al., 2013; Sharma et al., 2008) indicating that Ac-SDKP interferes with the IL-1β
receptor signaling. Since Ac-SDKP decreases NF-kB activation in vitro and in vitro [24, 25] we
predict that the inhibition of NF-kB is required for the Ac-SDKP-mediated MMP-9 downregulation. Our experimental design in this study allows us to demonstrate that Ac-SDKP protective effects are observed when treatment is initiated before ligation of the coronary artery.
Although a pre-treatment procedure can be interpreted as a limitation, many patients at “high
risk” of cardiovascular events are frequently treated with ACE inhibitors. We demonstrated
that Ac-SDKP prevents cardiac rupture, a fatal complication without any specific treatment,
and that the Ac-SDKP protective mechanisms might involve decreased pro-inflammatory M1
macrophage cardiac infiltration and MMP-9 expression.

Supporting information
S1 Fig. Flow cytometry raw original data supporting the Fig 3C and 3D. Events were
acquired using BD Fortessa flow cytometer and analyzed with FlowJo software. Original
images of each sample are shown. Quantitative data of the events per sample and per hearts
(corrected by the number of counting beads) is shown in the tables.
(PPTX)
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S2 Fig. Original zymograms supporting the Fig 6. Original zymograms obtained from sham,
myocardial infarction + vehicle (MI+veh), and myocardial infarction + Ac-SDKP (MI+AcSDKP) heart homogenates.
(PPTX)
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